Aligos Therapeutics IPO

10/15/2020

IPO

$150,000,000

Management says it will use the net proceeds from the IPO as follows:approximately $40.0 million to $43.0 million to advance our STOPS candidate, ALG-010133, including to fund the Phase 1 clinical trial and drug product manufacturing activities;approximately $35.0 million to $38.0 million to advance our CAM candidate, ALG-000184, including to fund the Phase 1 clinical trial and drug product manufacturing activities;approximately $12.0 million to $15.0 million to advance our ASO candidate, ALG-020572;approximately $20.0 million to $25.0 million to advance our siRNA candidate, ALG-125097;approximately $12.0 million to $14.0 million to advance our NASH THR-b candidate, ALG-055009; andthe remainder (if any) to fund discovery and research to broaden our pipeline of drug and backup candidates, including other discovery candidates for viral and liver diseases, development of our technology platform, and any potential future combination or other clinical trials and nonclinical studies.

Publicly-held

Biopharmaceutical

1 Corporate Drive 2nd Floor
South San Francisco, CA 94080
USA

Undisclosed

Not Recorded

Aligos Therapeutics (Nasdaq: ALGS) discovers targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).